PolyPid Begins Phase 2 Study to Assess Safety and Efficacy of D-PLEX100 in Prevention of Abdominal surgical site infections

Study to enroll up to 300 patients; with top-line results expected in the second half of 2019 Petah Tikva, Israel — October 15, 2018 – – PolyPid Ltd., a clinical-stage biopharmaceutical company focused on developing and commercializing new innovative therapies for post-surgical complications,